Pfizer explains their R&D Partnership Strategy




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Pfizer explains their R&D Partnership Strategy
Released on: August 08, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Getting the right excellence of science in where it is needed and combining it with their own excellence of science is one of the key challenges that today's Pharma industry has to address.
  • Summary
  • Transcript
  • Participants
  • Company
Getting the right excellence of science in where it is needed and combining it with their own excellence of science is one of the key challenges that today's Pharma industry has to address. Having defined ,over the last couple of years, their therapeutic areas of focus, Pfizer now aim to bring truly differentiated drugs forward to the patient. Partnering plays a large part in this and they have partnered across the board to achieve this. One of their initiatives , Centres for Therapeutic Innovation, allows them on highly promising projects to bring in academic investigators to work right next at the bench with their own scientists, hand in hand. Something which has not been frequently done in the past. During the World Pharma Licensing Summit in London last month Fiona Gardner talked to Uwe Schoenbeck, Chief Scientific Officer, External R&D Innovation, Senior Vice President, Worldwide R&D, about how R&D partnering works at Pfizer and the challenges and exciting areas of development.
Getting the right excellence of science in where it is needed and combining it with their own excellence of science is one of the key challenges that today's Pharma industry has to address. Having defined ,over the last couple of years, their therapeutic areas of focus, Pfizer now aim to bring truly differentiated drugs forward to the patient. Partnering plays a large part in this and they have partnered across the board to achieve this. One of their initiatives , Centres for Therapeutic Innovation, allows them on highly promising projects to bring in academic investigators to work right next at the bench with their own scientists, hand in hand. Something which has not been frequently done in the past. During the World Pharma Licensing Summit in London last month Fiona Gardner talked to Uwe Schoenbeck, Chief Scientific Officer, External R&D Innovation, Senior Vice President, Worldwide R&D, about how R&D partnering works at Pfizer and the challenges and exciting areas of development.
Uwe Schoenbeck
Pfizer
Pfizer
Pfizer Incorporated is a pharmaceutical company, ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. It produces Lipitor (atorvastatin, used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole), the antibiotic Zithromax (azithromycin), Viagra (sildenafil) for erectile dysfunction, and the anti-inflammatory Celebrex (celecoxib) (also known as Celebra in some countries outside the USA and Canada, mainly in South America).